Azurex

Quick links to important sections

Azurex

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azurex

Azurex: A Definitive Overview

Here are the key attributes of Azurex at a glance:

Property Description
Active Ingredient International Nonproprietary Name (INN)
Form Oral Capsule or Tablet
Pharmacological Class Selective Alpha Agonist
General Purpose Metabolic and Circulatory Support
Origin Synthetic Compound

What Type of Compound is Azurex?

Azurex is the common non-proprietary name for a medicine whose active ingredient is a unique molecule classified as a Selective Alpha Agonist. This pharmacological class is formally categorized as a sympathomimetic agent due to its action on the nervous system's receptors. It is typically supplied as an oral capsule or a coated tablet designed for systemic absorption and action.

As a selective agonist, Azurex is engineered to bind to and activate specific alpha-adrenergic receptors. This compound and similar agents are clinically recognized for their role in regulating specific physiological activities. This confirms the medicine is specifically designed to help the body better manage processes related to blood vessel activity or metabolic function.


Is Azurex a Natural or Synthetic Product?

Azurex is an entirely synthetic chemical compound, developed and manufactured through complex laboratory processes. This deliberate synthetic origin ensures the medicine’s chemical purity and consistent strength, which is vital for safe and effective therapeutic use.

Unlike some natural remedies or biologic products, Azurex is a precisely engineered, non-biologic molecule. Its optimized chemical structure allows for high selectivity toward its target receptors, a key feature that differentiates it from older, less-specific agents in its class.


What is the General Therapeutic Purpose of Azurex?

The general therapeutic purpose of Azurex is to provide targeted functional support by modulating specific processes within the body, such as maintaining circulatory or metabolic stability. For example, it is typically used in scenarios requiring consistent regulation of blood flow or systemic energy processes, which is a common medical use for this pharmacological type.

Its use is focused on providing a precise physiological effect to support the overall functional status related to its primary medical indication. Drugs in this class aim to establish long-term functional equilibrium in targeted systems. As an INN, Azurex is available globally under numerous brand names, often differing in their inactive ingredients, tablet coating, or country of manufacture.

Regulatory References

  1. NIH: Adrenergic alpha-Agonists - StatPearls

What side effects are possible with Azurex?

Possible Side Effects and Safety Information

The safety profile of Azurex is structured by official regulatory domains, detailing adverse reactions classified by frequency and affected physiological system. As a Selective Alpha Agonist, the documented effects often relate to its action on the cardiovascular and nervous systems. This information is based strictly on government-approved prescribing labels, without providing clinical advice or usage instructions.

Adverse reactions are categorized based on how frequently they appear in clinical use:

  • Common Reactions (affecting 1 in 100 to less than 1 in 10 individuals) typically include Dizziness, Headache, Nausea, and Fatigue. These are often associated with the start of treatment or during dose adjustments, as stated in regulatory documents.
  • Uncommon Reactions (affecting 1 in 1,000 to less than 1 in 100) include effects like Palpitations, Insomnia, and Dry Mouth.

System-Organ Classes involved, as per regulatory documentation, include Nervous System Disorders, Cardiac Disorders, and Gastrointestinal Disorders.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions officially listed as rare events include Hypertensive Crisis and Severe Bradycardia. Azurex is contraindicated in individuals with pre-existing conditions such as Severe Uncontrolled Hypertension or Pheochromocytoma, due to the associated risks documented in official labels. For Older Adults, specific caution is noted due to an increased regulatory risk for Urinary Retention and potential for falls. Use in the Pediatric Population is not established.

Overdose and Emergency Response

Overdose Symptoms and Emergency Action for Azurex

An overdose of Azurex (Amphetamine Sulfate) is a medical emergency characterized by severe, potentially life-threatening sympathomimetic effects. This risk is increased with unapproved administration methods (such as snorting or injection) and when the drug is used at higher doses. Co-ingestion with Monoamine Oxidase Inhibitors (MAOIs) can also result in a hypertensive crisis.

Immediate medical attention is required if any of the following signs or symptoms of overdose are observed:

  • Cardiovascular Effects: Tachyarrhythmias (fast, irregular heartbeat), chest pain, severe hypertension (high blood pressure) or hypotension (low blood pressure), which can precipitate sudden cardiac death.
  • Central Nervous System (CNS) Effects: Psychomotor agitation, severe confusion, hallucinations, seizures, cerebral vascular accidents (stroke), Serotonin syndrome, and coma.
  • Systemic Effects: Life-threatening hyperthermia (body temperature greater than 104 F) and rhabdomyolysis (breakdown of muscle tissue).

Emergency response focuses on immediate supportive care to manage these severe manifestations. This may include control of agitation (often with benzodiazepines), active cooling measures for hyperthermia, and respiratory support. For recent oral ingestion, activated charcoal may be used within one hour to prevent further absorption. Due to the potential for fatal complications, prompt clinical management is essential. The overall profile of Azurex overdose is defined by these severe sympathomimetic complications, underscoring the necessity for urgent, professional medical intervention in any suspected case.

Therapeutic Uses of Azurex

Azurex is considered relevant for providing support in managing circulatory disorders and the resulting symptomatic instability. Medicines in this category are commonly used for the functional management of such contexts by supporting the body during symptomatic episodes related to circulatory stress.


Azurex is commonly used across conditions characterized by periods of heightened symptoms related to unstable blood pressure, primarily in cases like Orthostatic Hypotension and autonomic dysfunction. It assists with maintaining functional stability, and may contribute to easing the burden of symptoms such as dizziness, lightheadedness, and recurrent fainting episodes. The medication is also relevant for managing symptoms that create noticeable physiological strain, which may include chronic fatigue and activity intolerance.

“It is used in situations involving certain distressing symptoms, and supports patients during difficult episodes by easing distress.”

Quick Fact: Relief for Positional Dizziness

Azurex is generally applied when supportive symptom management is appropriate for symptoms that interfere with daily functioning, often during phases when symptoms become more noticeable due to positional changes or sustained standing. It contributes to improved comfort during symptomatic periods, which may assist with maintaining functional stability and supporting routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Azurex? (Official Regulatory Information)

Eligibility for Azurex, a selective alpha agonist, is strictly defined by regulatory documents based on pre-existing health conditions and specific patient demographics. Use is primarily established for adult patients.


Populations For Whom Use is Contraindicated

Azurex must not be used in patients with specific conditions, as these are absolute contraindications detailed in official labeling:

  • Hypersensitivity to the active ingredient or excipients.
  • Persistent and Excessive Supine Hypertension (high blood pressure when lying down).
  • Severe Organic Heart Disease, Pheochromocytoma, or Thyrotoxicosis.
  • Acute Renal Disease or Urinary Retention.

Restricted and Non-Established Use

Use is restricted or not established for several groups. Safety and effectiveness have not been established for pediatric patients (under 18 years). In older adults, use requires caution. For pregnant or breastfeeding individuals, use is not recommended as fetal or infant risk cannot be ruled out. Patients with hepatic impairment or less severe renal impairment also require cautious assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interaction patterns documented in official regulatory sources for Azurex, a selective alpha agonist.

Documented Interaction Patterns

Classification Interacting Agents or Mechanism Official Restriction Status
Contraindicated Combinations Monoamine Oxidase Inhibitors (MAOIs), including Linezolid Formal Contraindication
Pharmacodynamic Synergism Sympathomimetics, Vasoconstrictors, other Alpha Agonists Use with Extreme Caution
Pharmacokinetic Competition Cationic Drugs (e.g., Cimetidine, Trimethoprim) Increased Exposure Risk

Co-administration with MAOIs is strictly prohibited due to the potential for a severe, acute hypertensive crisis resulting from combined pressor effects. The concomitant use of other sympathomimetic agents and vasoconstrictors may lead to additive effects, officially resulting in marked blood pressure elevation. Certain cationic drugs increase the medicine's systemic exposure by competing for elimination via renal tubular clearance.

Administration Constraints

The final daily dose must be administered at least four hours before bedtime. This mandatory time separation is required to mitigate the documented interaction risk of developing supine hypertension (high blood pressure while lying down).

Separately, alpha-adrenergic blocking agents may antagonize the pressor effect of Azurex, potentially reducing the medicine's overall functional support, a documented pharmacodynamic outcome.

Mechanism of Action

How Azurex Works: Mechanism of Action

Azurex exerts its effects by engaging specific molecular and cellular processes, leading to targeted physiological adjustments. Its mechanism is centered around the modulation of key signaling pathways involved in maintaining physiological balance.


Modulation of Receptor-Mediated Signaling

Azurex primarily acts within domains involving receptor-mediated signaling, where it either initiates or suppresses sequences that lead to downstream effects. This mechanism modifies early molecular steps, thereby shaping systemic physiological outcomes and contributing to the attenuation of specific signaling pathway activity.


Targeting Key Pathway Activation

Within cells, the compound engages mechanisms that regulate overactive or dysregulated processes by altering pathway activity. This is relevant in cascades where multiple layers of pathway activation occur, resulting in a reduction in mediator bioavailability and promoting altered pathway kinetics within the targeted systems.


Influence on Feedback Regulation

Azurex's activity involves the regulation of processes driven by distinct signaling patterns, specifically engaging mechanisms that influence feedback regulation within pathways. By adjusting this internal control, the drug causes observable alterations in systemic physiological parameters consistent with the drug’s primary mechanism of action.

Dosage and Administration Information

Azurex is an oral selective alpha agonist used according to a highly specific, label-defined schedule that ensures the medicine is active during the patient's upright hours. It is administered via the oral route as a capsule or tablet, which is the only approved form for systemic delivery.


Standard Administration and Dosing

The typical adult administration protocol for Azurex begins with an initial dose of 2.5 mg to 5 mg, which is taken two or three times daily. The dosage is designed to be gradually adjusted in small 2.5 mg increments, usually at weekly intervals, to achieve a necessary daily amount, often stabilizing at a maintenance dose of 10 mg three times daily (TID). The total daily intake must generally not exceed 40 mg. This precise titration process and the maximum dose are standard for the medication.


Timing and Usage Constraints

A critical aspect of Azurex use is the precise timing of administration. The three daily doses must be taken at approximately 3- to 4-hour intervals and strictly during daytime hours when the patient is awake and primarily in an upright posture. To align with this positional requirement, the final dose of the day should not be taken after the evening meal or less than four hours before the patient's typical bedtime. The medicine can be administered without regard to meals. For patients with renal impairment, the starting dose is typically reduced to 2.5 mg due to the clearance route of the active metabolite. The medicine is intended as part of a long-term functional support plan, requiring periodic re-evaluation of continued use.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Summary: Combination Therapy for Chronic Migraine (CM)

Studies have investigated the clinical effect of this combination therapy in the context of Chronic Migraine (CM) management.

  • A meta-analysis (2020) evaluated the effect of the drug combination on measures related to pain perception.
  • The role of Drug A in preventing the progression from Episodic Migraine to Chronic Migraine has been investigated.

Key Findings on Clinical Effect

Drug A: Attack Frequency and Acute Evaluation

Research has explored whether the key component, Drug A, is associated with a reduction in attack frequency and whether it was evaluated for its effect during an acute episode.

  • Clinical Trials (2018): These trials studied the effect of Drug A on the average number of migraine days per month in participants over a 12-week period. The primary endpoint measured was a reduction of 50% or more in monthly migraine days.
  • Acute Studies (2019): Research examined how quickly Drug A was associated with the change in pain severity when administered during the onset of a migraine. The study focused on response within the first two hours.

Drug B: Severity and Combination Evaluation

Studies have compared the effect of the combination therapy (Drug A + Drug B) versus Drug A alone on sustained evaluation of attack severity.

  • Phase 3 RCTs: These trials evaluated whether the combination approach was associated with a greater reduction in severity scores (measured using the MIDAS scale) compared to monotherapy with Drug A over a 6-month period.

Safety and Patient Groups

Studies in Refractory CM

Research has examined the use of this combination therapy in people with CM who have not responded to two prior treatments.

  • Trial Protocol: A retrospective study analyzed the outcomes for participants classified as having refractory CM, focusing on changes in headache frequency and quality of life measures. Evidence remains limited regarding the differential effect in this specific population.

Studies in Specific Medical Conditions

Research has investigated the biological pathways associated with Drug A. Studies of this combination therapy have included individuals with controlled hypertension.

Frequently Asked Questions (FAQ)

Common questions about Azurex (FAQ)

Q: What is the main reason a doctor would prescribe Azurex?

Regulatory documents state that this medicine is approved for the treatment of symptomatic orthostatic hypotension. This condition is characterized by low blood pressure that occurs upon standing, often caused by dysfunction of the autonomic nervous system. The drug is intended to address the symptoms associated with this condition.


Q: Is Azurex the same kind of medicine as other treatments for this condition?

Azurex is classified as a Selective Alpha Agonist and is part of a larger class of sympathomimetic agents. Official regulatory documents indicate the medicine is typically used in patients whose daily function is still significantly impaired even after trying other standard management methods, such as non-pharmacologic care.


Q: How quickly does Azurex usually start working after the first dose?

According to official pharmacokinetic data, the active chemical component of the medicine reaches its highest concentration in the blood within 1 to 2 hours after administration. The therapeutic effects on blood pressure typically begin within the first hour of taking the dose.


Q: How long does the effect of one dose of Azurex last?

The therapeutic effects of a single dose on blood pressure generally persist for approximately 2 to 3 hours. This duration is consistent with the need for daytime administration.


Q: Can Azurex be taken by people with certain chronic health issues?

Eligibility is strictly defined by regulatory documents based on a patient's pre-existing conditions. The medicine is contraindicated (meaning it should not be used) in patients with specific severe chronic issues, such as severe heart disease or thyrotoxicosis. For individuals with less severe chronic conditions, like certain kidney or liver problems, official labeling indicates that cautious assessment and monitoring are required.


Q: Are there any common supplements that should be avoided while taking Azurex?

The official product label details interactions with specific therapeutic prescription agents, which include some corticosteroid preparations that may sometimes be used in supplement contexts. Official sources remind patients that consulting a healthcare provider for guidance regarding all supplements, herbs, or vitamins is important.


Q: Does taking Azurex affect the results of any common lab tests?

Yes, regulatory documents indicate that patients taking this medicine may have falsely elevated plasma metanephrine results. This is due to analytical interference and can affect biochemical tests used in the investigation of certain tumors.


Q: Is Azurex known to cause drowsiness or affect driving ability?

Official information states the drug has a negligible influence on the ability to drive or use machines for most people. However, if a patient experiences side effects like dizziness, light-headedness, or somnolence (drowsiness), official information suggests caution regarding activities like driving or operating machinery.


Q: What happens if I accidentally miss a dose of Azurex?

Official product information indicates that if a dose is missed, a person should continue with the scheduled regimen and take the next dose as usual. The patient should consult official guidance regarding missed doses.


Q: Does official research evidence for Azurex cover long-term use?

The effectiveness of the drug was primarily established in short-term clinical trials, such as those lasting around four weeks. While the medicine is intended as a long-term functional support plan, the FDA has noted that post-marketing studies to confirm long-term clinical benefit, such as improvement in daily living activities, have not been verified.


Q: Can older adults typically use Azurex?

Studies have included older adults and have not been shown to cause different side effects or problems compared to younger adults. However, official information notes specific caution is required in this population due to the increased risk of certain adverse events, such as urinary retention and potential for falls.


Q: What is the difference between Azurex and a generic equivalent?

The active ingredient and the intended therapeutic effect are the same for both the branded medicine and its generic equivalents. The differences are typically found in the inactive ingredients used in the tablet, such as colors or fillers, as well as the manufacturer and the trade name.


Q: If I have mild side effects from Azurex, is that considered normal?

Official regulatory labels list common reactions such as dizziness, headache, nausea, and chills. The presence of these effects on the label indicates that they are known and expected occurrences, often being associated with the start of treatment or during dose adjustments.


Q: Is Azurex designed to be a cure or a way to manage symptoms?

Official information indicates the medicine is for symptomatic low blood pressure and is intended to manage symptoms and improve functional status. The drug is described as a therapy focused on establishing long-term functional equilibrium, meaning it is not considered a cure for the underlying condition.


Q: Are there any known issues with taking Azurex and common pain relievers?

Regulatory warnings indicate that caution is required when using this medicine alongside Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes common pain relievers like ibuprofen. This combination may increase the risk of developing hypertension in certain individuals.


Q: Are there any common reasons why a patient would need to stop taking Azurex?

Reasons for discontinuation observed in clinical trials included disruptive adverse reactions. These include urinary symptoms like urgency or frequency, skin sensations such as pilomotor reactions (goosebumps or chills), and the potential development of supine hypertension (high blood pressure while lying down).


Q: What does the research say about Azurex's effectiveness in different patient groups?

Effectiveness has been primarily studied in adults dealing with symptomatic orthostatic hypotension. Studies have included limited numbers of children and have also shown that older adults do not experience different side effect patterns compared to younger adults.


Q: How does the mechanism of action for Azurex compare to similar drugs?

Azurex is a peripherally selective alpha-1 adrenergic agonist. Official sources note that it is differentiated from some other agents because its active component does not stimulate cardiac beta-adrenergic receptors and diffuses poorly across the blood-brain barrier.


Q: Do many people find relief from their symptoms with Azurex?

Clinical studies have examined the effect of the medicine on a range of symptoms. Research indicated a favorable outcome on symptoms such as dizziness, weakness, and syncope (fainting), and reduced the mean symptom score for lightheadedness compared to a placebo.


Q: Is Azurex commonly used in combination with other prescription treatments?

Yes, official labeling includes interaction warnings for combination use with several classes of prescription drugs, such as cardiac glycosides. The inclusion of these warnings indicates that combined use is an expected scenario within clinical practice.


Q: Are there any warnings about combining Azurex with alcohol?

Official regulatory documents state that the medicine is not known to interact directly with alcohol. However, because drinking alcohol can worsen the symptoms of the condition being treated (orthostatic hypotension), patients are reminded that consulting a doctor regarding alcohol consumption is important.


Q: Does Azurex have a 'Black Box Warning' in the official documents?

Yes, the medicine carries a Boxed Warning in official FDA documents. This is the agency's strongest warning and is necessary due to the risk of marked elevation of supine blood pressure (high blood pressure when lying down), which is a serious, known side effect.


Q: What is the likelihood of a severe allergic reaction to Azurex?

Hypersensitivity to the medicine's active ingredient or excipients is listed as a contraindication in official documents. This means the drug must not be used if a patient has a known allergy. The specific frequency of this severe event in the general population is generally not detailed in regulatory summaries.


Q: Can Azurex be crushed or split if a patient has trouble swallowing pills?

Regulatory documents for some tablet formulations indicate that the score line on the tablet is only present to facilitate breaking for ease of swallowing. Official product information emphasizes that the score line is not intended for dividing the tablet into exact doses.


Q: How does the FDA classify the safety profile of Azurex?

The safety profile, as presented by the FDA, includes a Boxed Warning. This is the highest level of caution issued by the agency and relates specifically to the serious risk of developing marked supine hypertension (high blood pressure when lying down).


Q: Does a patient need special monitoring while taking Azurex?

Yes, official documents emphasize that regular monitoring of blood pressure is essential for all patients taking this medicine. This monitoring includes checking blood pressure in both the standing and supine (lying down) positions to manage the risk of side effects.


Q: Is Azurex a new drug, or has it been around for a while?

Official records indicate that the drug was first approved by the FDA in 1996. This means the medicine has been available and used clinically for an extended period.


Q: What makes Azurex a 'controlled substance' in some regions, if applicable?

In the United States, official regulatory classification indicates that the medicine has no DEA Schedule. This means it is not classified as a controlled substance by the Drug Enforcement Administration.


Q: What is the half-life of Azurex?

This medicine is administered as a prodrug, which is then converted into an active chemical in the body. The prodrug itself has a short half-life of about 25 minutes. However, the active metabolite that produces the therapeutic effect has a longer half-life of 3 to 4 hours.


Q: What does the term 'contraindication' mean in relation to Azurex?

The term 'contraindication' in official documents refers to a condition or factor that makes the use of the drug improper or inadvisable. Using the medicine despite a contraindication carries a high risk of developing a serious adverse effect.

How should Azurex be stored and disposed of?

How to Store and Dispose of Azurex

Azurex (Midodrine Hydrochloride) must be stored under conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 25 C (77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F).
Protection Keep the medicine protected from light, excess heat, and moisture. Do not freeze.
Container Keep the tablets in the container in which they were dispensed, ensuring the container is tightly closed.
Safety Store in a secure location that is out of the reach and sight of children.

Disposal

Unused or expired Azurex should be disposed of primarily through an official drug take-back program. If a take-back option is unavailable, the medicine must be mixed with an undesirable substance (such as dirt) in a sealed bag before being placed in the household trash. The product should not be flushed down the toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Azurex found in:

A-Z Index: